SIMCERE PHARMACEUTICAL GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.3 HKD | +1.15% |
|
+2.91% | -21.25% |
| Apr. 25 | Simcere Pharmaceutical’ Profit Down 23% in 2023 | MT |
| Apr. 10 | Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA | MT |
| Sales 2024 * | 1.03B 8.08B | Sales 2025 * | 1.2B 9.39B | Capitalization | 1.72B 13.46B |
|---|---|---|---|---|---|
| Net income 2024 * | 140M 1.1B | Net income 2025 * | 180M 1.41B | EV / Sales 2024 * | 1.39 x |
| Net cash position 2024 * | 280M 2.19B | Net cash position 2025 * | 367M 2.87B | EV / Sales 2025 * | 1.13 x |
| P/E ratio 2024 * |
12.5
x | P/E ratio 2025 * |
9.75
x | Employees | 7,027 |
| Yield 2024 * |
2.8% | Yield 2025 * |
3.48% | Free-Float | 28.7% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +1.15% | ||
| 1 week | +2.91% | ||
| Current month | -0.19% | ||
| 1 month | -2.75% | ||
| 3 months | -7.02% | ||
| 6 months | -15.74% | ||
| Current year | -21.25% |
1 week
5.11
5.30
1 month
5.035.48
Current year
4.946.74
1 year
4.949.58
3 years
4.9414.98
5 years
4.9414.98
10 years
4.9414.98
| Managers | Title | Age | Since |
|---|---|---|---|
Jin Sheng Ren
CEO | Chief Executive Officer | 61 | 94-12-31 |
Yu Shan Wan
DFI | Director of Finance/CFO | 53 | 00-04-30 |
Gaobo Zhou
CIO | Chief Investment Officer | 45 | 22-01-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jin Sheng Ren
CEO | Chief Executive Officer | 61 | 94-12-31 |
Xin Hua Wang
BRD | Director/Board Member | 69 | 19-11-18 |
Yu Shan Wan
DFI | Director of Finance/CFO | 53 | 00-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.22% | 4 M€ | -27.92% | ||
| 0.24% | 2 M€ | -14.14% | ||
| 0.01% | 117 M€ | +0.16% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 5.3 | +1.15% | 6 342 000 |
| 24-04-25 | 5.24 | 0.00% | 6,405,000 |
| 24-04-24 | 5.24 | +0.38% | 6,014,000 |
| 24-04-23 | 5.22 | +0.19% | 4,920,000 |
| 24-04-22 | 5.21 | +1.17% | 4,392,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am EDT
More quotes
Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces innovative drugs, such as Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.849
CNY
Average target price
7.984
CNY
Spread / Average Target
+64.64%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.25% | 1.72B | |
| +20.44% | 21.89B | |
| +8.94% | 14.45B | |
| +13.07% | 13.63B | |
| +37.46% | 11.49B | |
| -8.59% | 6.85B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.35% | 5.06B | |
| -5.36% | 4.66B |
- Stock Market
- Equities
- 2096 Stock
